Standing out in the field of IgY Immunotechnology

  • Home
    Home A full collection of all the Research Archive entries.
  • Years
    Years Sort entries by year.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of research entries that were created previously.

Lentivirus Mediated Correction of Artemis-Deficient Severe Combined Immunodeficiency.*

Posted by on in 2017
  • Font size: Larger Smaller
  • Hits: 1085
  • Print

Punwani D1Kawahara M1Yu J1Sanford U1Roy S1Patel K1Carbonaro DA2Karlen AD3Khan S1Cornetta K4Rothe M5Schambach A5Kohn DB2Malech HL6McIvor RS3Puck JM1Cowan MJ1. 2017. Hum Gene Ther. 28(1):112-124. doi: 10.1089/hum.2016.064. Epub 2016 Sep 7.
Department of Pediatrics, University of California School of Medicine and University of California San Francisco Benioff Children's Hospital , San Francisco, San Francisco, California.
2Departments of Microbiology, Immunology and Molecular Genetics and Pediatrics, University of California Los Angeles , Los Angeles, California.
3Department of Genetics, Cell Biology and Development, University of Minnesota , Minneapolis, Minnesota.
4Department of Medical and Molecular Genetics, Indiana University, and the Indiana University Viral Production Facility, Indianapolis, Indiana.
5 nstitute for Experimental Hematology, Hannover Medical School , Hannover, Germany.
6Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, Division of Intramural Research, National Institutes of Health , Bethesda, Maryland.


During B and T lymphocyte maturation, V(D)J recombination is initiated by creation of DNA double-strand breaks. Artemis is an exonuclease essential for their subsequent repair by nonhomologous end-joining. Mutations in DCLRE1C, the gene encoding Artemis, cause T-B-NK+ severe combined immunodeficiency (ART-SCID) and also confer heightened sensitivity to ionizing radiation and alkylating chemotherapy. Although allogeneic hematopoietic cell transplantation can treat ART-SCID, conditioning regimens are poorly tolerated, leading to early mortality and/or late complications, including short stature, endocrinopathies, and dental aplasia. However, without alkylating chemotherapy as preconditioning, patients usually have graft rejection or limited T cell and no B cell recovery. Thus, addition of normal DCLRE1C cDNA to autologous hematopoietic stem cells is an attractive strategy to treat ART-SCID. We designed a self-inactivating lentivirus vector containing human Artemis cDNA under transcriptional regulation of the human endogenous Artemis promoter (AProArt). Fibroblasts from ART-SCID patients transduced with AProArt lentivirus showed correction of radiosensitivity. Mobilized peripheral blood CD34+ cells from an ART-SCID patient as well as hematopoietic stem cells from Artemis-deficient mice demonstrated restored T and B cell development following AProArt transduction. Murine hematopoietic cells transduced with AProArt exhibited no increase in replating potential in an in vitro immortalization assay, and analysis of AProArt lentivirus insertions showed no predilection for sites that could activate oncogenes. These efficacy and safety findings support institution of a clinical trial of gene addition therapy for ART-SCID.

Buy it here: 

 * Secondary antibodies (HRP-Donkey anti-Chicken IgY) used in this publication were manufactured by Gallus Immunotech Inc.


Artemis; gene therapy; lentivirus; radiation sensitivity; severe combined immunodeficiency

[PubMed - in process]
Last modified on